← Evidence map

ArticleHealth economics review2026

Reducing breast cancer recurrences with CDK4/6 inhibitor treatment of HR-positive, HER2-negative early stage breast cancer from a societal perspective.

Stephanie Reitzinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Reducing breast cancer recurrences with CDK4/6 inhibitor treatment of HR-positive, HER2-negative early stage breast cancer from a societal perspective. | OpenQuestion